Sun Pharmaceutical Industries Limited
₹1,792.00+₹31.00 (+1.76%)
Sun Pharmaceutical Industries Limited’s quoted price sits in the lower half of its reported 52-week range, 12.5% below the high.
NSE · THEMISMED.NS · INR
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 06:17 AM UTC. Cached market data; not a live quote.
One-year closing-price history · INR. Historical prices are not a forecast.
Themis Medicare Limited’s quoted price sits in the lower half of its reported 52-week range, 30.22% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Themis Medicare Limited’s forward annual dividend is ₹0.50 per share, paid annual. The forward yield is 0.51% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Themis Medicare Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Themis Medicare Limited, along with its affiliated entities, is a pharmaceutical company that produces and supplies medicinal goods for both the Indian and international markets. Its product portfolio encompasses active pharmaceutical ingredients (APIs) and various drug formulations, designed for application across diverse medical domains such as anti-infectious conditions, malaria, tuberculosis, cardiovascular issues, health and wellness, cancer, eye diseases, and pain relief. Founded in 1969, the company operated under the name Themis Chemicals until 2001, when it officially changed to Themis Medicare Limited. The company's primary operations are directed from its Mumbai, India headquarters.
Latest available per-share figures in INR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 06:21 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
₹1,792.00+₹31.00 (+1.76%)
Sun Pharmaceutical Industries Limited’s quoted price sits in the lower half of its reported 52-week range, 12.5% below the high.
₹147.05-₹2.45 (-1.64%)
KMC Speciality Hospitals (India) Limited’s quoted price sits in the upper half of its reported 52-week range, 20.81% below the high.
₹2,305.80-₹1.80 (-0.08%)
Hester Biosciences Limited’s quoted price sits in the upper half of its reported 52-week range, 14.08% below the high.
₹474.30-₹6.65 (-1.38%)
Virtuoso Optoelectronics Limit’s quoted price sits in the upper half of its reported 52-week range, 20.01% below the high.
₹517.40+₹7.50 (+1.47%)
Lincoln Pharmaceuticals Limited’s quoted price sits in the lower half of its reported 52-week range, 32.81% below the high.
₹26.89+₹0.29 (+1.09%)
Sigachi Industries Limited’s quoted price sits in the lower half of its reported 52-week range, 34.12% below the high.
₹148.90-₹1.36 (-0.91%)
Max India Limited’s quoted price sits in the lower half of its reported 52-week range, 32.32% below the high.
₹179.83-₹2.10 (-1.15%)
Wanbury Limited’s quoted price sits in the lower half of its reported 52-week range, 49.89% below the high.